Most stock quote data provided by BATS. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. Proteostasis Therapeutics Inc's percentage of analysts bullish on the stock is higher than 28.53% of Pharmaceutical Products stocks. Proteostasis Therapeutics, Inc. (NASDAQ:PTI) issued its quarterly earnings results on Monday, November, 16th. Vote “Outperform” if you believe PTI will outperform the S&P 500 over the long term. In that case, then, we find that the current price level is +354.55% off the targeted high while a plunge would see the stock lose 70.45% from current levels. They called the 2020 crash 45 days early. Learn more. Based on 1 analyst offering 12 month price targets for Proteostasis Therapeutics in the last 3 months. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. Learn more. - PTI - Stock Price Today - Zacks SHAREHOLDER ALERT: WeissLaw LLP Reminds PTI and NETE Shareholders About Its Ongoing Investigations, SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Proteostasis Therapeutics has a P/B Ratio of 14.57. All times are ET. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Proteostasis Therapeutics' mailing address is 80 Guest Street Suite 500, Boston MA, 02135. W&T Offshore Inc. analyst ratings, historical stock prices, earnings estimates & actuals. Learn more. Man Who Predicted March 2020 Crash Makes Bold Tech Stock Prediction. In the past three months, Proteostasis Therapeutics insiders have not sold or bought any company stock. PTI's price/sales ratio is 17.1; that's higher than the P/S ratio of 93.08% of US stocks. View our full suite of financial calendars and market data tables, all for free. Above the chart, you will find the 12-Month High, Mean, and Low Target Prices from analysts who provided ratings. There are currently 4 buy ratings for the stock, resulting in a consensus rating of "Buy.". MarketBeat's community ratings are surveys of what our community members think about Proteostasis Therapeutics and other stocks. Current $1.11. During the day the stock fluctuated 7.48% from a day low at $19.52 to a day high of $20.98. Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter. The number of analysts covering the stock of PTI is higher than 22.93% of Pharmaceutical Products stocks. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Average $4.67. One share of PTI stock can currently be purchased for approximately $17.77. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. On average, they anticipate Proteostasis Therapeutics' stock price to reach $4.67 in the next year. Shares of Adani Ports gained as much as 4.7% to Rs 474.9 apiece. Proteostasis Therapeutics EPS beats by $0.02, Proteostasis Therapeutics Reports Third Quarter 2020 Financial Results. The dark blue line represents the company's actual price. © 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. The price has fallen in 7 of the last 10 days and is down by -4.38% for this period. Want to see which stocks are moving? Low $2 High $8. View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Price target in 14 days: 1.928 USD. View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings. 326 E 8th St #105, Sioux Falls, SD 57103 | [email protected] | (844) 978-6257 Yumanity Therapeutics, Inc. Common Stock (YMTX) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. Do Not Sell My Information. The stock has traded between $1.03 and $1.08 so far today. US stock market today: stock quotes, stock screener, stock charts, insiders ... TCO, UROV, and PTI Shareholders About Its Ongoing Investigations Monday, 23 November 2020 yahoo. MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Cantor Fitzgerald is very positive to PTI and gave it "Buy" rating on June 04, 2020. After Yumanity Therapeutics (YMTX) announced that its reverse merger with Proteostasis Therapeutics (PTI) closed on December 22, Piper Sandler analyst Edward Tenthoff reiterated his Overweight rating on Yumanity shares updated his price target to $36 to account for the completion of the merger, completion of a 20:1 reverse stock split and closure of the … The average price target is $5.20, with a high forecast of $8.00 and a low forecast of $3.00. View %COMPANY_NAME% PTI investment & stock information. Price/Cash Flow: Latest closing price divided … © American Consumer News, LLC dba MarketBeat® 2010-2021. View our full suite of financial calendars and market data tables, all for free. In a report issued on April 24, Brian Abrahams from RBC Capital reiterated a Buy rating on Proteostasis Therapeutics (PTI – Research Report), with a price target of $7.00.The company’s shares closed last Friday at $1.31. Amount of Analyst Coverage Proteostasis Therapeutics has received no research coverage in the past 90 days. Analysts have been projecting $3 as a low price target for the stock while placing it at a high target of $8. Please log in to your account or sign up in order to add this asset to your watchlist. Receive a free world-class investing education from MarketBeat. On average, analysts give the stock a Strong Buy rating. Get short term trading ideas from the MarketBeat Idea Engine. The P/E ratio of Proteostasis Therapeutics is -21.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. MarketBeat thinks these five stocks may be even better buys.View MarketBeat's top stock picks here. (Add your “underperform” vote.). To see all exchange delays and terms of use please see disclaimer. According to analysts' consensus price target of $4.67, Proteostasis Therapeutics has a forecasted downside of 73.7% from its current price of $17.77. The company traded as low as $1.13 and last traded at $1.15. Price/Sales: Latest closing price divided by the last 12 months of revenue/sales per share. You can opt out at any time. To see all exchange delays and terms of use please see disclaimer. The lighter blue line represents the stock's consensus price target. 4 Wall Street analysts have issued twelve-month target prices for Proteostasis Therapeutics' shares. MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Learn more. Through Berkshire Hathaway…Warren Buffett recently dumped $800 million of Apple stock… INO, $INO, Inovio Pharmaceuticals Inc stock technical analysis with charts, breakout and price targets, support and resistance levels, and more trend analysis indicators This price target is based on 5 analysts offering 12 month price targets for Proteostasis Therapeutics in the last 3 months. The high price target for PTI is $7.00 and the low price target for PTI is $3.00. The average price target represents a … 4 Wall Street analysts have issued ratings and price targets for Proteostasis Therapeutics in the last 12 months. Looking for new stock ideas? MarketBeat just released five new trading ideas, but Proteostasis Therapeutics wasn't one of them. All 25 analysts tracking the company have a ‘buy’ rating on the stock. Target & Analyst Ratings. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Get the latest Zacks research report on PTI — FREE 10 ETFs With Most Upside To Analyst Targets Proteostasis Therapeutics Stock Forecast, PTI stock price prediction. Fundamental company data provided by Zacks Investment Research. Their average twelve-month price target is $4.67, predicting that the stock has a possible downside of 73.74%. Proteostasis Therapeutics, Inc. was founded in 2006 and is headquartered in Boston, Massachusetts. Proteostasis Therapeutics has received a consensus rating of Buy. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data. Learn everything you need to know about successful options trading with this three-part video course. Looking for new stock ideas? 4 Wall Street analysts have issued ratings and price targets for Proteostasis Therapeutics in the last 12 months. And bought this instead! © 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Past. Some companies that are related to Proteostasis Therapeutics include Hypera (HYPMY), Apellis Pharmaceuticals (APLS), Insmed (INSM), Legend Biotech (LEGN), Karuna Therapeutics (KRTX), Agios Pharmaceuticals (AGIO), MorphoSys (MOR), Amicus Therapeutics (FOLD), Pacira BioSciences (PCRX), Rocket Pharmaceuticals (RCKT), Alkermes (ALKS), OPKO Health (OPK), ALX Oncology (ALXO), Corcept Therapeutics (CORT) and Viela Bio (VIE). Abrahams covers the … Proteostasis Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, March 9th 2021. Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Get daily stock ideas top-performing Wall Street analysts. The price target was set to $4.00. Proteostasis Therapeutics is headquartered at 80 Guest Street Suite 500, Boston MA, 02135. Identify stocks that meet your criteria using seven unique stock screeners. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. View our earnings forecast for Proteostasis Therapeutics. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. (PTI) raised $51 million in an initial public offering on Thursday, February 11th 2016. View which stocks are hot on social media with MarketBeat's trending stocks report. (Add your “outperform” vote. Proteostasis Therapeutics Inc (NASDAQ:PTI) shares dropped 5.7% during mid-day trading on Tuesday . Their forecasts range from $3.00 to $7.00. The company issued 3,900,000 shares at a price of $12.00-$14.00 per share. View which stocks are hot on social media with MarketBeat's trending stocks report. Their average twelve-month price target is $4.67, predicting that the stock has a possible downside of 73.63%. The company can be reached via phone at 617-225-0096 or via email at [email protected]. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). PTI | A complete PTI overview by MarketWatch. All rights reserved. The Proteostasis Therapeutics Inc. stock price gained 5.07% on the last trading day (Friday, 19th Feb 2021), rising from $19.51 to $20.50. WTI updated stock price target summary. Proteostasis Therapeutics trades on the NASDAQ under the ticker symbol "PTI.". According to analysts' consensus price target of $4.67, Proteostasis Therapeutics has a forecasted downside of 74.6% from its current price of $18.40. The median PTI price target (a different metric than the average or mean) was $ as of, the highest PTI price target in the range was $ while the lowest PTI price target in the range was $, with a standard deviation of $. The company reported ($0.16) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.17) by $0.01. MarketBeat does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security. Start Your Risk-Free Trial Subscription Here, Warren Buffett again encourages investors to bet on America, Biden hails House passage of $1.9T virus bill, now to Senate, Pandemic leaves tribes without US recognition at higher risk, The Latest: U.S. FDA approves J&J single-shot vaccine, Biden team readies wider economic package after virus relief, In oil-rich Iraq, a few women buck norms, take rig site jobs, The Latest: Collins: Reconsider U.S.-Canada border limits, Cronos Stock Pulls Back After Earnings, It Might Be Time To Buy Some, Guardion Health Sciences Stock Needs to Give Investors More Than Survival, Wait For a Better Price Before Placing a Bet On Churchill Downs, 3 Small Cap Dividend Stocks with Growth Prospects, It’s Okay to Take the Over on DraftKings Stock, 7 Undervalued Stocks That Deserve More Attention, 7 Semiconductor Stocks Set to Gain From the Chip Shortage, 7 Great Dividend Stocks to Buy For a Comfortable Retirement, 7 Penny Stocks That Don’t Care About Robinhood, 7 Hotel Stocks Just Waiting For the Vaccine, 7 Stocks to Watch When Student Debt Forgiveness Gets Passed, 7 Healthcare Stocks Delivering Innovation in 2021, 7 Lithium Stocks That Will Power the Electric Vehicle Boom, 7 Electric Vehicle (EV) Stocks That Have Real Juice, 7 Post-Inauguration Stocks to Buy For Under $20, Receive Analysts' Upgrades and Downgrades Daily. Vote “Underperform” if you believe PTI will underperform the S&P 500 over the long term. Proteostasis Therapeutics does not currently pay a dividend. Receive a free world-class investing education from MarketBeat. Learn everything you need to know about successful options trading with this three-part video course. Identify stocks that meet your criteria using seven unique stock screeners. MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Proteostasis Therapeutics has received no research coverage in the past 90 days. Want to see which stocks are moving? Asad Umar was removed and persons from the IMF and World Bank were brought through a conspiracy to … ET by Tomi Kilgore Exicure shares rise on immuno-oncology trial It follows that stock’s current price would jump +429.8% in reaching the projected high whereas dropping to the targeted low would mean a loss of 98.68% for stock’s current value. Leerink Partners and RBC Capital Markets acted as the underwriters for the IPO and Baird and H.C. Wainwright & Co. were co-managers. PTI has a greater average analyst price target than 10.11% of all US stocks. Fundamental company data provided by Zacks Investment Research. © American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved. Wall Street is positive on Proteostasis Therapeutics Inc (PTI). The company's lead product candidates for the treatment of CF include PTI-801, a cystic fibrosis transmembrane conductance regulator (CFTR) corrector agent; PTI-808, a CFTR potentiator; and PTI-428, a CFTR amplifier. Proteostasis Therapeutics has a market capitalization of $927.33 million and generates $5 million in revenue each year. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: You have already added five stocks to your watchlist. Proteostasis Therapeutics has received 58.18% “underperform” votes from our community. The high price target for PTI is $7.00 and the low price target for PTI is $3.00. MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. A high-level overview of Patni Computer Systems Limited (PTI-OLD) stock. This suggests that the stock has a possible downside of 73.7%. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. Learn about financial terms, types of investments, trading strategies and more. View the latest market news and prices, and trading information. The company was formerly known as Proteoguard, Inc. and changed its name to Proteostasis Therapeutics, Inc. in September 2007. Wall Street analysts have given Proteostasis Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Nobody expects what they're predicting now... Proteostasis Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of novel therapeutics to treat cystic fibrosis. The average price target is $2.00 with a high forecast of $2.00 and a low forecast of $2.00. View Proteostasis Therapeutics' earnings history. Export data to Excel for your own analysis. PTI stock research, analysis, profile, news, analyst ratings, key statistics, fundamentals, stock price, charts, earnings, guidance and peers. Export data to Excel for your own analysis. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: You have already added five stocks to your watchlist. Proteostasis Therapeutics does not have a long track record of dividend growth. He’s now moved $3.8 BILLION in a tiny niche of the tech sector billionaires are flocking to…document.write(''); Sign-up to receive the latest news and ratings for PTI and its competitors with MarketBeat's FREE daily newsletter. Get the latest %COMPANY_NAME% PTI detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. ), Proteostasis Therapeutics has received 441 “underperform” votes. 4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Proteostasis Therapeutics in the last twelve months. You may vote once every thirty days. Get daily stock ideas top-performing Wall Street analysts. For PTI, its debt to operating expenses ratio is greater than that reported by only 0.34% of US equities we're observing. Do Not Sell My Information. MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. It is based on a 60-month historical regression of the return on the stock onto the return on the S&P 500. Only 16.64% of the stock of Proteostasis Therapeutics is held by institutions. Proteostasis Therapeutics' management team includes the following people: A Powerful Day Trading Strategy that can produce $300 - $500 in just 15 Minutes, Reserve your free virtual seat to an exclusive trading session with legendary trader Tyson Clayton, Start Your Risk-Free Trial Subscription Here, Warren Buffett again encourages investors to bet on America, Biden hails House passage of $1.9T virus bill, now to Senate, Pandemic leaves tribes without US recognition at higher risk, The Latest: U.S. FDA approves J&J single-shot vaccine, Biden team readies wider economic package after virus relief, In oil-rich Iraq, a few women buck norms, take rig site jobs, The Latest: Collins: Reconsider U.S.-Canada border limits, Cronos Stock Pulls Back After Earnings, It Might Be Time To Buy Some, Guardion Health Sciences Stock Needs to Give Investors More Than Survival, Wait For a Better Price Before Placing a Bet On Churchill Downs, 3 Small Cap Dividend Stocks with Growth Prospects, It’s Okay to Take the Over on DraftKings Stock, 7 Undervalued Stocks That Deserve More Attention, 7 Semiconductor Stocks Set to Gain From the Chip Shortage, 7 Great Dividend Stocks to Buy For a Comfortable Retirement, 7 Penny Stocks That Don’t Care About Robinhood, 7 Hotel Stocks Just Waiting For the Vaccine, 7 Stocks to Watch When Student Debt Forgiveness Gets Passed, 7 Healthcare Stocks Delivering Innovation in 2021, 7 Lithium Stocks That Will Power the Electric Vehicle Boom, 7 Electric Vehicle (EV) Stocks That Have Real Juice, 7 Post-Inauguration Stocks to Buy For Under $20, Here's Why We're Watching Proteostasis Therapeutics' (NASDAQ:PTI) Cash Burn Situation, Proteostasis Therapeutics, Inc. 326 E 8th St #105, Sioux Falls, SD 57103 | [email protected] | (844) 978-6257 The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock. Stockholders Approve Business Combination with Yumanity Therapeutics, Inc.; Board Sets Reverse Stock Split Ratio, Yumanity Therapeutics to Raise $33.6 Million PIPE Contingent on Completion of Reverse Merger with Proteostasis. Proteostasis Therapeutics, Inc. (PTI) estimates and forecasts The company earns $-59,130,000.00 in net income (profit) each year or ($1.16) on an earnings per share basis. The official website for Proteostasis Therapeutics is www.proteostasis.com. You can opt out at any time. Based on aggregate information from My MarketBeat watchlists, some companies that other Proteostasis Therapeutics investors own include Idera Pharmaceuticals (IDRA), BHP Group (BHP), Sorrento Therapeutics (SRNE), OPKO Health (OPK), Amarin (AMRN), Matinas BioPharma (MTNB), Micron Technology (MU), Rite Aid (RAD), VBI Vaccines (VBIV) and Acasti Pharma (ACST). >Historical Ratings The table shows the mean historical analyst recommendation for the current period, along with the previous 1, 2, and 3 periods. Exicure started at outperform with $6 stock price target at BMO Capital Dec. 18, 2020 at 8:49 a.m. Learn about financial terms, types of investments, trading strategies and more. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. The PTI members should also know. Earnings for Proteostasis Therapeutics are expected to grow in the coming year, from ($0.71) to ($0.61) per share. The consensus among Wall Street equities research analysts is that investors should "buy" Proteostasis Therapeutics stock. The average price target represents a 73.91% increase from the last price of $1.15. View analyst ratings for Proteostasis Therapeutics or view top-rated stocks. PTI Stock Summary. Proteostasis Therapeutics (PTI) Sees Hammer Chart Pattern: Time to Buy? WeissLaw LLP Reminds PTI, MVC, and EIDX Shareholders About Its Ongoing Investigations ... Price target. Price target in 14 days: 46.461 USD. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. PTI.DE updated stock price target summary. View Price Target for PTI Access over 100 stock metrics like Beta, EV/EBITDA, PE10, Free Cash Flow Yield, KZ Index and Cash Conversion Cycle. The projected low price target is $3 while the price target rests at a high of $8. Market indices are shown in real time, except for the DJIA, which is delayed by two minutes.
Walk Board Rental Near Me, Hitman 2 Isle Of Sgail Knight Guards, Epic Rc Plane Crashes, How To Instant Double Jump, Nippon 95 Shaft, Symbols Of Service, Van Wert High School Football State Championship, Spinach Soul 7718, Funny Name Calling From Movies, Rocket M5 Range,